Business Context and Reporting Period
Company: Senseonics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 26, 2020
Context: The Company is conducting a strategic review to evaluate strategic alternatives. Due to the global COVID-19 pandemic and its impact on access to physician offices, the Company is implementing immediate operational changes to preserve liquidity.
Key Financial Metrics and Liquidity
Revenue and Profit: The filing does not provide specific revenue or profit figures for the current period.
Cash Flow: The Company expects cash used in operating activities for the quarter ending March 31, 2020, to be consistent with average quarterly operating cash outflows during 2019. However, cost reduction measures are expected to significantly reduce cash used in operations in future quarters.
Liquidity and Financing: The Company is in discussions with new financing sources, which could include issuing additional equity, secured or unsecured indebtedness, or a combination of both. The filing notes that a widespread pandemic could reduce the ability to access capital, negatively affecting liquidity.
Material Changes and Operational Actions
- Suspension of Sales: Effective immediately, the Company is suspending commercial sales of its 90-day Eversense continuous glucose monitoring (CGM) system to new patients and physician practices in the United States.
- Existing Patients: Distribution of the 90-day Eversense system will continue for patients currently using the product. Support for existing patients and physicians will continue.
- Eversense Bridge Program: The Company is evaluating this program and may revise, suspend, or cancel it entirely.
- Development Continuity: Development and regulatory submission efforts for the Eversense XL CGM system (180-day use) will continue.
- Workforce: Substantially all of the workforce is working from home due to Maryland government orders and internal policies.
Guidance, Outlook, and Risks
Guidance Withdrawal: Due to the COVID-19 pandemic, the Company is withdrawing and suspending its financial guidance previously provided for the year ending December 31, 2020. A business update is expected on the first-quarter earnings call.
Strategic Outlook: The Company continues to explore strategic alternatives to enhance stakeholder value.
Material Risks:
- Supply Chain Disruption: Manufacturing facilities and suppliers are located in Germany, the UK, China, Japan, and the US. Quarantines or restrictions could disrupt the supply of materials for sensors and transmitters.
- Clinical Trial Delays: Site initiation and patient enrollment may be delayed as hospitals prioritize COVID-19 resources. Patient movement restrictions may impede protocol compliance.
- Market Demand: Insertions of Eversense have slowed as patients may be unable or unwilling to visit healthcare providers, or providers may prioritize acute illnesses over diabetes management.
- Economic Impact: Global financial market disruptions could reduce access to capital and materially affect the value of common stock.
Investor Verification Checklist
- Verify the status of discussions regarding new financing sources (equity or debt) to ensure liquidity sufficiency.
- Monitor the timeline for the resumption of commercial sales to new patients for the 90-day Eversense system.
- Track progress on the Eversense XL regulatory submission to confirm it remains on schedule despite pandemic disruptions.
- Review upcoming first-quarter earnings communications for updated financial guidance and cash burn rate projections.
- Assess the impact of supply chain interruptions in Germany, the UK, and China on future product availability.